Abstract
2-Amino-2-[2-(4-octylphenyl)ethyl] propane-1,3-diol hydrochloride (FTY720), a synthetic product derived from a metabolite ofIsaria sinclairii, has been demonstrated to have a potent immunosuppressive activity that induces apoptotic cell death in T cells and several other cell lines. In this study, using the human T-lymphoma cell line, Jurkat cells, we investigated the apoptotic signal transduction mediated by FTY720, in particular comparing its role on the cleavage of caspases, with that mediated by etoposide or anti-Fas antibody. All of these agents cleaved caspases, inducing their active form in the affected cells. Pretreatment with a broad caspase inhibitor [benzyloxycarbonyl-Val-Ala-Asp-(Ome) fluoromethyl ketone] markedly decreased the incidence of apoptotic cells induced by FTY720, etoposide, and anti-Fas antibody, through the abrogation of cleavage of Bid, poly(ADP-ribose) polymerase, and caspases 3, 8, and 9. The overexpression of Bcl-2 gene prevented FTY720- and etoposide-mediated apoptosis, but not Fas-mediated apoptosis. In addition, mitochondria were demonstrated to play a critical role in FTY720-triggered cell death, suggesting that this drug has a potent anticancer activity.
Footnotes
-
↵1 These authors contributed equally to this work.
-
This study was supported by grants from Minister of Health and Welfare (9KO-2; Grant for Science Research), Minister of Education (Grants 07457265, 09470273, 09671271, 09671270, and 09307025), Agency of Science and Technology, and Human Science Foundation in Japan.
- Abbreviations:
- PARP
- poly(ADP-ribose) polymerase
- apaf-1
- apoptotic protease-activating factor-1
- Z-VAD-FMK
- benzyloxycarbonyl-Val-Ala-Asp-(Ome) fluoromethyl ketone
- Z-Asp-CH2-DCB
- benzyloxycarbonyl-Asp-CH2COC-2,6-dichlorobenzene
- Ac
- acetyl
- YVAD
- Try-Val-Ala-Asp
- CHO
- aldehyde
- DEVD
- Asp-Glu-Val-Asp
- IETD
- Ile-Glu-Thr-Asp
- LEHD
- Leu-Glu-His-Asp
- DMSO
- dimethyl sulfoxide
- PBS
- phosphate-buffered saline
- Received September 10, 2001.
- Accepted November 20, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|